Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840902 · ClinicalTrials.gov registry record · Phase 2
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT03840902 is a Phase 2 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 153 participants.
The verdict
NCT03840902, a Phase 2 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Interventions
- DRUG Placebo
- DRUG Pemetrexed
- DRUG Etoposide
- DRUG Durvalumab
- DRUG M7824
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2023-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03840902
The ClinicalTrials.gov registry entry for NCT03840902 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03840902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03840902 about?
NCT03840902 is a clinical study titled "M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)". The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
What is the current status of trial NCT03840902?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2019-04-16. Estimated completion is 2023-02-17.
What interventions are being tested in trial NCT03840902?
The interventions under investigation include: Placebo (DRUG), Pemetrexed (DRUG), Etoposide (DRUG), Durvalumab (DRUG), M7824 (DRUG).
Who is sponsoring clinical trial NCT03840902?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.